Colistin: A mainstay antibiotic for treatment of fatal Gram negative bacterial infections
Abstract
Our world is facing an enormous disaster due to spreading of the life-threatening bacterial infections, especially after the spread of multidrug-resistant Gram-negative bacteria (MDR-GNB), including those resistant to known antibiotics such as fluoroquinolones, aminoglycosides, broad-spectrum penicillins, and other β-lactams antibiotics, such as monobactams and carbapenem. In addition, the a shortage of the production of new drugs that are able to overcome these life-threatening infections. This disaster has pushed the medical profession to re-use colistin, the old antibiotic, as the last hope drug for the treatment of these fatal infections. Colistin was discovered in 1950 and was rejected in most parts of the world due to its toxicity including nephrotoxicity. Unfortunately, the resistance against colistin has been discovered and this resistance has spread globally. Colistin resistance includes both intrinsic resistance and acquired resistance. The mechanisms of acquired colistin resistance were linked only to the chromosomal gene mutations until the discovery of the colistin resistance gene named the mobile colistin-resistant (mcr) gene which is mediated by the plasmid. In this review, we discuss the history, chemistry, spectrum of activity, mechanism of action, clinical uses and indications, adverse effects, mechanisms of colistin resistance, and antibiotic combinations with colistin.nd indications, adverse effects, mechanisms of colistin resistance and antibiotic…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.